270 related articles for article (PubMed ID: 26490423)
1. Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma.
Devlin JR; Hannan KM; Hein N; Cullinane C; Kusnadi E; Ng PY; George AJ; Shortt J; Bywater MJ; Poortinga G; Sanij E; Kang J; Drygin D; O'Brien S; Johnstone RW; McArthur GA; Hannan RD; Pearson RB
Cancer Discov; 2016 Jan; 6(1):59-70. PubMed ID: 26490423
[TBL] [Abstract][Full Text] [Related]
2. AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo.
Devlin JR; Hannan KM; Ng PY; Bywater MJ; Shortt J; Cullinane C; McArthur GA; Johnstone RW; Hannan RD; Pearson RB
FEBS J; 2013 Nov; 280(21):5307-16. PubMed ID: 23331925
[TBL] [Abstract][Full Text] [Related]
3. The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.
Rebello RJ; Kusnadi E; Cameron DP; Pearson HB; Lesmana A; Devlin JR; Drygin D; Clark AK; Porter L; Pedersen J; Sandhu S; Risbridger GP; Pearson RB; Hannan RD; Furic L
Clin Cancer Res; 2016 Nov; 22(22):5539-5552. PubMed ID: 27486174
[TBL] [Abstract][Full Text] [Related]
4. Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis.
Kusnadi EP; Trigos AS; Cullinane C; Goode DL; Larsson O; Devlin JR; Chan KT; De Souza DP; McConville MJ; McArthur GA; Thomas G; Sanij E; Poortinga G; Hannan RD; Hannan KM; Kang J; Pearson RB
EMBO J; 2020 Nov; 39(21):e105111. PubMed ID: 32945574
[TBL] [Abstract][Full Text] [Related]
5. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
[TBL] [Abstract][Full Text] [Related]
6. AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer.
Chan JC; Hannan KM; Riddell K; Ng PY; Peck A; Lee RS; Hung S; Astle MV; Bywater M; Wall M; Poortinga G; Jastrzebski K; Sheppard KE; Hemmings BA; Hall MN; Johnstone RW; McArthur GA; Hannan RD; Pearson RB
Sci Signal; 2011 Aug; 4(188):ra56. PubMed ID: 21878679
[TBL] [Abstract][Full Text] [Related]
7. The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy.
Woods SJ; Hannan KM; Pearson RB; Hannan RD
Biochim Biophys Acta; 2015 Jul; 1849(7):821-9. PubMed ID: 25464032
[TBL] [Abstract][Full Text] [Related]
8. Combined inhibition of RNA polymerase I and mTORC1/2 synergize to combat oral squamous cell carcinoma.
Shi S; Luo H; Wang L; Li H; Liang Y; Xia J; Wang Z; Cheng B; Huang L; Liao G; Xu B
Biomed Pharmacother; 2021 Jan; 133():110906. PubMed ID: 33190037
[TBL] [Abstract][Full Text] [Related]
9. Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death.
Domostegui A; Peddigari S; Mercer CA; Iannizzotto F; Rodriguez ML; Garcia-Cajide M; Amador V; Diepstraten ST; Kelly GL; Salazar R; Kozma SC; Kusnadi EP; Kang J; Gentilella A; Pearson RB; Thomas G; Pelletier J
Blood; 2021 Jun; 137(24):3351-3364. PubMed ID: 33512431
[TBL] [Abstract][Full Text] [Related]
10. Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.
Bihani T; Ezell SA; Ladd B; Grosskurth SE; Mazzola AM; Pietras M; Reimer C; Zinda M; Fawell S; D'Cruz CM
Oncotarget; 2015 Feb; 6(4):2407-20. PubMed ID: 25537515
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic MYC Induces the Impaired Ribosome Biogenesis Checkpoint and Stabilizes p53 Independent of Increased Ribosome Content.
Morcelle C; Menoyo S; Morón-Duran FD; Tauler A; Kozma SC; Thomas G; Gentilella A
Cancer Res; 2019 Sep; 79(17):4348-4359. PubMed ID: 31292158
[TBL] [Abstract][Full Text] [Related]
12. Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells.
Katsha A; Wang L; Arras J; Omar OM; Ecsedy J; Belkhiri A; El-Rifai W
Clin Cancer Res; 2017 Jul; 23(14):3756-3768. PubMed ID: 28073841
[No Abstract] [Full Text] [Related]
13. c-Myc overexpression increases ribosome biogenesis and protein synthesis independent of mTORC1 activation in mouse skeletal muscle.
Mori T; Ato S; Knudsen JR; Henriquez-Olguin C; Li Z; Wakabayashi K; Suginohara T; Higashida K; Tamura Y; Nakazato K; Jensen TE; Ogasawara R
Am J Physiol Endocrinol Metab; 2021 Oct; 321(4):E551-E559. PubMed ID: 34423683
[TBL] [Abstract][Full Text] [Related]
14. S6 Kinase is essential for MYC-dependent rDNA transcription in Drosophila.
Mitchell NC; Tchoubrieva EB; Chahal A; Woods S; Lee A; Lin JI; Parsons L; Jastrzebski K; Poortinga G; Hannan KM; Pearson RB; Hannan RD; Quinn LM
Cell Signal; 2015 Oct; 27(10):2045-53. PubMed ID: 26215099
[TBL] [Abstract][Full Text] [Related]
15. CMTM6 attenuates cisplatin-induced cell death in OSCC by regulating AKT/c-Myc-driven ribosome biogenesis.
Mohapatra P; Mohanty S; Ansari SA; Shriwas O; Ghosh A; Rath R; Majumdar SKD; Swain RK; Raghav SK; Dash R
FASEB J; 2022 Oct; 36(10):e22566. PubMed ID: 36165231
[TBL] [Abstract][Full Text] [Related]
16. The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence.
Wall M; Poortinga G; Stanley KL; Lindemann RK; Bots M; Chan CJ; Bywater MJ; Kinross KM; Astle MV; Waldeck K; Hannan KM; Shortt J; Smyth MJ; Lowe SW; Hannan RD; Pearson RB; Johnstone RW; McArthur GA
Cancer Discov; 2013 Jan; 3(1):82-95. PubMed ID: 23242809
[TBL] [Abstract][Full Text] [Related]
17. First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study.
Khot A; Brajanovski N; Cameron DP; Hein N; Maclachlan KH; Sanij E; Lim J; Soong J; Link E; Blombery P; Thompson ER; Fellowes A; Sheppard KE; McArthur GA; Pearson RB; Hannan RD; Poortinga G; Harrison SJ
Cancer Discov; 2019 Aug; 9(8):1036-1049. PubMed ID: 31092402
[TBL] [Abstract][Full Text] [Related]
18. Targeting RNA-Polymerase I in Both Chemosensitive and Chemoresistant Populations in Epithelial Ovarian Cancer.
Cornelison R; Dobbin ZC; Katre AA; Jeong DH; Zhang Y; Chen D; Petrova Y; Llaneza DC; Steg AD; Parsons L; Schneider DA; Landen CN
Clin Cancer Res; 2017 Nov; 23(21):6529-6540. PubMed ID: 28778862
[No Abstract] [Full Text] [Related]
19. The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer.
Yan S; Frank D; Son J; Hannan KM; Hannan RD; Chan KT; Pearson RB; Sanij E
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28117679
[TBL] [Abstract][Full Text] [Related]
20. c-MYC G-quadruplex binding by the RNA polymerase I inhibitor BMH-21 and analogues revealed by a combined NMR and biochemical Approach.
Musso L; Mazzini S; Rossini A; Castagnoli L; Scaglioni L; Artali R; Di Nicola M; Zunino F; Dallavalle S
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):615-629. PubMed ID: 29229300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]